Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Stevanato Group S.p.A. (NYSE:STVN) have earned a consensus recommendation of “Hold” from the five ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company.

A number of equities research analysts recently commented on STVN shares. Morgan Stanley lowered their price target on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a research report on Friday, March 6th. Weiss Ratings downgraded shares of Stevanato Group from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 11th. Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a research note on Tuesday, February 10th. Citigroup lowered their target price on shares of Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Finally, KeyCorp cut their price target on shares of Stevanato Group from $37.00 to $32.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th.

Stevanato Group Stock Performance

Shares of STVN opened at €18.66 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.11 and a current ratio of 1.63. The stock has a 50 day moving average price of €15.93 and a two-hundred day moving average price of €17.96. The firm has a market capitalization of $5.65 billion, a P/E ratio of 31.63, a P/E/G ratio of 1.66 and a beta of 0.75. Stevanato Group has a 52 week low of €12.89 and a 52 week high of €28.00.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Friday, May 8th. The company reported €0.11 EPS for the quarter, missing the consensus estimate of €0.12 by (€0.01). The company had revenue of €273.57 million during the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 earnings per share. Equities analysts forecast that Stevanato Group will post 0.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stevanato Group

Hedge funds have recently modified their holdings of the company. Glenmede Trust Co. NA grew its holdings in shares of Stevanato Group by 29.5% in the first quarter. Glenmede Trust Co. NA now owns 38,461 shares of the company’s stock valued at $529,000 after acquiring an additional 8,770 shares in the last quarter. Royal Bank of Canada lifted its holdings in Stevanato Group by 15.8% during the first quarter. Royal Bank of Canada now owns 421,696 shares of the company’s stock worth $5,798,000 after acquiring an additional 57,536 shares during the period. Lazard Asset Management LLC purchased a new position in Stevanato Group in the first quarter worth $1,749,000. Sei Investments Co. grew its stake in Stevanato Group by 4.0% in the 1st quarter. Sei Investments Co. now owns 266,218 shares of the company’s stock valued at $3,661,000 after purchasing an additional 10,203 shares during the period. Finally, Van Berkom & Associates Inc. grew its stake in Stevanato Group by 2,944.2% in the 1st quarter. Van Berkom & Associates Inc. now owns 170,994 shares of the company’s stock valued at $2,351,000 after purchasing an additional 165,377 shares during the period.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.